Mineralys Non Currrent Assets Other vs Total Current Liabilities Analysis
| MLYS Stock | 12.53 0.66 5.56% |
Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Non Currrent Assets Other and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Non Currrent Assets Other vs Total Current Liabilities
Non Currrent Assets Other vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Non Currrent Assets Other account and Total Current Liabilities. At this time, the significance of the direction appears to have weak relationship.
The correlation between Mineralys Therapeutics,'s Non Currrent Assets Other and Total Current Liabilities is 0.39. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Non Currrent Assets Other and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Mineralys Therapeutics, Common are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Currrent Assets Other i.e., Mineralys Therapeutics,'s Non Currrent Assets Other and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.39 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Total Current Liabilities
Total Current Liabilities is an item on Mineralys Therapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mineralys Therapeutics, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 769.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 130.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 27K | 1.7M | 1.9M | 2.0M | Depreciation And Amortization | 18.7M | 228.5K | 167.9K | 159.5K |
Mineralys Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Mineralys Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.